Introduction
============

Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtype of non-Hodgkin lymphoma with considerable clinical and biological heterogeneity.^[@bib1]^ Although a durable complete remission can be achieved by using rituximab combined with chemotherapy in a substantial proportion of patients, up to 30\~40% of DLBCL cases are either relapsed or refractory to current standard treatment.^[@bib2]^ Therefore, the identification of actionable biomarkers will be helpful in improving the clinical outcome of high-risk DLBCL patients.^[@bib3]^

Initially uncovered as the target of t(8;14)(q24;q32) chromosome translocation in Burkitt lymphoma,^[@bib4]^ MYC is a master regulator in DLBCL pathogenesis^[@bib5]^ and renders lymphoma cell resistance to chemotherapy.^[@bib6]^ Clinically, MYC overexpression is related to increased risk of disease relapse and indicates poor disease outcome in DLBCL patients.^[@bib7]^ As direct targeting of MYC appears difficult,^[@bib8]^ alternative therapeutic strategies to specifically modulate MYC-driven downstream effectors warrants further investigation.^[@bib9],\ [@bib10]^

Correlating with genomics, transcriptomics and proteomics, metabolomics is the end-point of 'multi-omics' cascades and provides a 'real-world' assessment of cancer cell physiology.^[@bib11]^ Generally involved in genetic transcription, MYC alters multiple tumor metabolic processes such as glycolysis, nucleotide and lipid synthesis.^[@bib12]^ Previous works indicated that MYC regulates lipid metabolism during lymphomagenesis.^[@bib13]^ It has recently been reported that, as an indispensible component of lipid synthesis, choline metabolism is dysregulated in lymphoma.^[@bib14]^ However, the exact relationship between choline metabolism and lymphomagenic MYC expression remains undetermined.

Lipid metabolism has been exploited as a promising target for cancer treatment.^[@bib15]^ Berberine (BBR) is an alkaloid initially extracted from Chinese herbs and possesses multiple anti-metabolism properties, in particular the lipid-lowering effects.^[@bib16]^ Under a clinically achievable concentration, BBR is both effective and safe in treating hyperlipidemia patients via the modulation of lipid profile.^[@bib17]^ Experimentally, BBR can inhibit tumor cell growth in hematological malignancies, inducing cell apoptosis and caspase-independent cell death.^[@bib18],\ [@bib19]^ Therefore, to determine whether BBR has therapeutic effect on lymphoma lipid metabolism is of considerable interest.

The present study showed that MYC dysregulates choline metabolism and impedes lymphoma cell necroptosis in a mitophagy-dependent manner by transcriptionally activating the key enzyme phosphate cytidylyltransferase 1 choline-α (PCYT1A). Through targeting *PCYT1A* expression, the lipid-lowering alkaloid BBR inhibited the MYC-driven aberration of choline metabolism and induced lymphoma cell necroptosis, providing a potential lipid-modifying strategy in treating MYC-High lymphoma.

Material and methods
====================

Patients
--------

Metabolic profile was assessed on the serum samples of 80 *de novo* patients with DLBCL, including the training set (*N*=30) and the validation set (*N*=50). Histological diagnoses were established according to the World Health Organization classification.^[@bib20]^ Quantitative detection of metabolites was further performed on serum samples of 108 *de novo* DLBCL cases. All patients were treated by rituximab combined with chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone). Patients clinical characteristics were listed in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. Written informed consents were obtained from patients in accordance with the Declaration of Helsinki. The study was approved by Shanghai Rui Jin Hospital Review Board.

Cells and reagents
------------------

DLBCL cell line DB with MYC overexpression and Burkitt lymphoma cell line Ramos with MYC translocation (American Type Culture Collection, Manassas, VA, USA) were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum in a humidified atmosphere of 95% air and 5% CO~2~ at 37 °C. HEK-293T cell was cultured in DMEM medium supplemented with 10% heat-inactivated fetal bovine serum. MYC inhibitor 10058-F4 and mitophagy inhibitor Mdivi-1 were obtained from Selleck (Houston, TX, USA). BBR was from Sigma-Aldrich (St Louis, MO, USA). Nucleic acid synthesis inhibitor Actinomycin was from Abcam (Cambridge, UK).

Cell viability
--------------

Cell (5 × 10^5^/ml) were seeded in 96-well plates and incubated with indicated concentration of reagents. Cell growth was assessed by CCK8 (1:10, Dojindo, Kumamoto, Japan) and the absorbance was measured at 450 nm by spectrophotometry. The percentage of cell growth inhibition was calculated as treated or transfected cells divided by untreated or non-transfected cells.

RNA extraction and quantitative real-time PCR
---------------------------------------------

Total mRNA was extracted using TRIzol reagent (Invitrogen, Shanghai, China). Complementary DNA was synthesized using PrimeScript RT Reagent Kit with gDNA Eraser (TaKaRa, Dalian, China). Quantitative real-time PCR was performed by SYBR Premix Ex TaqTM II (TaKaRa) and ABI ViiA 7 (Applied Biosystems, Bedford, MA, USA) with primers against *PCYT1A* (Forward: 5′-GCCAAGGTCAATGCAAGGAA-3′, Reverse: 5′-AAACTCTCACAGGTCGCTCA-3′), *PLA2G4C* (Forward: 5′-CAGGAGTGGGACTTGGCTAA-3′, Reverse: 5′-TCTTCCACGGGCTTCTTCAT-3′). *GAPDH* (Forward: 5′-GCTCATTTCCTGGTATGACAAC-3′, Reverse: 5′-CTGTGAGGAGGGGAGATTCA-3′) was used as an endogenous control.

Metabolomic assay
-----------------

Serum samples (100 μl) were assessed by ultra performance liquid chromatography (UPLC) and quadruple/time-of-flight mass spectrometry. The mass spectrometer was operated in both positive and negative electrospray ionization (ESI+/ESI−) mode. The UPLC-quadruple/time-of-flight mass spectrometry ESI+ and ESI− raw data were analyzed by the MarkerLynx Applications Manager version 4.1 (Waters Corp., Milford, MA, USA) and total ion chromatography was generated. To identify different metabolomic profile between MYC-high and MYC-low groups, multivariate analysis was performed using SIMCA-P software version 12.0 (Umetrics AB, Umeå, Sweden). The unsupervised principal component analysis and supervised orthogonal partial least squares-discriminant analysis (OPLS-DA) models were constructed. Reliability of OPLS-DA models was validated by response permutation test. Quality controls were prepared by mixing the same volume of each sample and repeatedly injected during the assay to monitor instrumental stability and avoid systematic bias. As for cell metabolites, lymphoma cells (1 × 10^7^/ml) were extracted by freeze-thaw method and cell lysate (100 μl) was used for UPLC-triple quadrupole mass spectrometry analysis. The detailed parameters were as previously reported.^[@bib14]^

Gene network and pathway analysis
---------------------------------

Human Genome U133 Plus 2.0 Array GeneChip microarray (Affymetrix, Santa Clara, CA, USA) was performed on frozen tumor samples of nine non-GCB DLBCL cases. Genes filtered by KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways were subsequently hierarchical clustered using MEV v.4.8.1 (Dana-Farber Cancer Institute, Boston, MA, USA).

Cell transfection
-----------------

Cells (1 × 10^6^/ml) were transfected with luciferase reporter GV238-promoter (GeneChem, Shanghai, China), pRL-TK Vector (Promega, Madison, WI, USA), PCYT1A-overexpressing vector pCMV6-*PCYT1A*, MYC-overexpressing vector pCMV6-*MYC* or vehicle pCMV6-ct (Origene, Rockville, MD, USA) using SuperFect transfection reagent (Qiagen, Hilden, Germany). Cells were transfected with *MYC* small interfering RNA (siRNA) (Cell Signaling, Beverly, MA, USA), three *PCYT1A* siRNAs (siRNA1: 5′-rArCrCrUrArArGrGrArCrArGrCrUrArCrArArArGrGrArAAG-3′, siRNA2: 5′-rArGrGrUrCrArArUrGrCrArArGrGrArArGrArGrGrArGrAAA-3′, siRNA3: 5′-rCrGrUrGrArUrCrUrCrArArCrArGrGrGrArArArUrUrGrUCA-3′) or negative control siRNA (Origene), three *PCYT1A* short hairpin RNAs (shRNAs) or negative control shRNA (Origene) using HiperFect transfection reagent (Qiagen) according to manufacturer's instruction.

Western blotting
----------------

Western blotting was performed as described previously.^[@bib21]^ Anti-MYC monoclonal antibody (Abcam, 1:1000), anti-PCYT1A monoclonal antibody (Cell Signaling, 1:1000), anti-p-AKT monoclonal antibody (Cell Signaling, 1:1000), anti-p-ERK monoclonal antibody (Cell Signaling, 1:1000) and Anti-CDK6 monoclonal antibody (Cell Signaling, 1:1000) were used. Anti-Actin antibody (Cell Signaling, 1:2000) was used to ensure equivalent loading of total protein.

Co-immunoprecipitation assay
----------------------------

Co-immunoprecipitation assay was performed with 5 × 10^7^ cells using Pierce Co-Immunoprecipitation Kit (Thermo, Pierce, Rockford, IL, USA) according to the manufacturer's protocols. Anti-RIP1 monoclonal antibody (BD Pharmingen, San Diego, CA, USA, 1:1000), anti-MLKL monoclonal antibody (Cell Signaling, 1:1000) and anti-RIP3 monoclonal antibody (Cell Signaling, 1:1000) were used.

Luciferase reporter assay
-------------------------

Luciferase activities were detected by Centro XS3 LB960 Luminometer (Berthold, Bad Wildbad, Germany) and Dual-Luciferase Reporter Assay System (Promega, Beijing, China).

Chromatin immunoprecipitation assay
-----------------------------------

Chromatin immunoprecipitation assays were performed with 2 × 10^7^ cells using EZ-ChIP Kit (Millipore, Billerica, MA, USA). PCR and quantitative real-time PCR were performed with primer against the promoter of the *PCYT1A* (Forward: 5′-AGTTGGACACGGGAGCAG, Reverse: CGGAGGATGCAGCGAAGA-3′). Antibody against RNA Polymerase II was referred as positive control. Nonspecific IgG was referred as negative control.

Immunohistochemistry
--------------------

Immunohistochemistry was performed on 5 μm paraffin sections using anti-MYC monoclonal antibody (1:200) and anti-PCYT1A monoclonal antibody (1:100, Abcam), as previously reported.^[@bib21]^ Protein expression levels were scored based on percentage of stained cells.^[@bib22]^

Confocal microscopy
-------------------

Acetone-fixed cells were co-incubated with anti-mitochondria monoclonal antibody MTC (1:100, Abcam) and anti-LC3A/B monoclonal antibody (1:200, Cell Signaling) as primary antibody and diaminotriazinylaminofluorescein-labeled donkey anti-rabbit/mouse-IgG antibody (1:400, Abcam) as secondary antibody. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole. Confocal laser-scanning microscopy was applied to observe the co-localization of fluorescent staining.

Transmission electron microscopy
--------------------------------

Cells and tissue samples were fixed for 2 h in 2% glutaraldehyde/0.1 [M]{.smallcaps} phosphate-buffered saline (pH 7.3) at 4 °C, rinsed with 0.1 [M]{.smallcaps} phosphate-buffered saline twice for 10 min at 4 °C, postfixed in 1% osmium tetroxide/0.1 [M]{.smallcaps} phosphate-buffered saline for 2 h at 4 °C, dehydrated in graded ethanol, saturated in graded Epikote (Hexion, Columbus, OH, USA) and embedded in Epon 812 (TAAB Laboratories, Reading, UK). Ultrathin sections were prepared with LKB V ultra microtome (LKB, Bromma, Sweden), stained with lead citrate and viewed by Philip CM-120 transmission electron microscopy (Philips, Eindhoven, The Netherlands).

Murine models
-------------

SCID mice (5to 6 weeks old, Shanghai Laboratory Animal Center, Shanghai, China) were injected subcutaneously with 2 × 10^7^ DB cells into the flank. In the murine model established with DB cells transfected with *PCYT1A* shRNA or negative control (CON shRNA, five mice each group), tumor volume was calculated as 0.5 × *a*(length) × *b*(width)^2^ since the date of formation (day 0). In murine model established with DB cells, treatments (10 mice per group) were started once tumor reached about 0.5 cm × 0.5 cm in surface (day 0). The untreated group received dimethyl sulfoxide, whereas the treated group received BBR once daily for 14 days (5 mg/kg/day). Mice were allocated to different groups randomly. Animals were used according to protocols approved by the Shanghai Rui Jin Hospital Animal Care and Use Committee.

Micro positron emission tomography/computed tomography imaging
--------------------------------------------------------------

Mice were subjected to positron emission tomography/computed tomography analysis 1 week after treatment. Positron emission tomography/computed tomography imaging was performed on an Inveon MM Platform (Siemens Preclinical Solutions, Knoxville, TN, USA) as previously reported.^[@bib14]^ Radio tracer ^11^C-Choline was synthesized and injected to anesthetized mice through the tail vein.^[@bib23]^ Mean standardized uptake values were determined as dividing the relevant regions of interest concentration by the ratio of the injected activity to the body weight.

Statistical analysis
--------------------

Two-tailed Student's *t*-test was applied to compare two groups with similar variance. Association between different factors or parameters was determined by *χ*^2^-test. *P*\<0.05 was considered significant. Values were presented as mean±s.e.m. Assays were set up in triplicate unless otherwise noted in the Figure legends. Statistical analyses were performed on SPSS 13.0 software (IBM Corp., Armonk, NY, USA).

Results
=======

MYC was overexpressed in DLBCL and induced aberrant choline metabolism
----------------------------------------------------------------------

As revealed by immunohistochemistry, MYC was highly expressed (MYC staining⩾40%)^[@bib22]^ in 44% (47/108) of DLBCL patients ([Figure 1a](#fig1){ref-type="fig"}) and significantly correlated with extranodal involvement and an International Prognostic Index, indicating intermediate--high or high risk ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Patients were subsequently divided into two groups according to MYC expression: MYC-High (MYC staining⩾40%) and MYC-Low (MYC staining\<40%).

Serum samples obtained from 30 *de novo* DLBCL cases (15 each for MYC-High and MYC-Low group, [Supplementary Table S3](#sup1){ref-type="supplementary-material"}) were analyzed by UPLC-quadruple/time-of-flight mass spectrometry. Representative total ion chromatography was shown in [Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}. Based on 2708 features obtained after normalization, including 787 spectral features for ESI+ and 1921 spectral features for ESI−, principle component analysis score plots showed a separating trend between MYC-High, MYC-Low groups and repeated quality controls ([Figure 1b](#fig1){ref-type="fig"}, left panel). OPLS-DA models revealed satisfactory modeling and predictive ability with one predictive component and one orthogonal component for both ESI+ (R2Y=0.86, Q2=0.5) and ESI− (R2Y=0.886, Q2=0.592, [Figure 1b](#fig1){ref-type="fig"}, middle panel), as validated by response permutation test ([Figure 1b](#fig1){ref-type="fig"}, right panel).

A total of 47 significantly altered serum metabolites with variable importance for projection\>1 in the above-mentioned OPLS-DA models and Student's *t*-test *P*-value\<0.05 between MYC-High and MYC-Low group were identified ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). These metabolites were further performed for the enrichment of KEGG pathways using ConsensusPathDB (<http://cpdb.molgen.mpg.de>), resulting in choline metabolism in cancer (KEGG hsa05231) and glycerophospholipid metabolism pathway (KEGG hsa00564) with the highest significance ([Figure 1c](#fig1){ref-type="fig"}). Meanwhile, gene expression profile of frozen tumor tissue samples from nine non-GCB DLBCL cases ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}) confirmed that MYC-High DLBCL had a distinct gene pattern of cancerous choline metabolism and glycerophospholipid metabolism pathway ([Figure 1d](#fig1){ref-type="fig"}, left panel). Choline metabolism-related genes *PCYT1A*, *PLA2G4C* and *PDGFC*, as well as glycerophosphoslipid metabolism-related genes *PCYT1A*, *PLA2G4C*, *ACHE*, *PHOSPHO1* and *LPGAT2* were identified by Student's *t*-test with *P*-value\<0.05 ([Figure 1d](#fig1){ref-type="fig"}, right panel). This association between MYC overexpression and aberrant choline metabolism was then confirmed by serum metabolomics assay in a validation set of 50 DLBCL cases (25 each for MYC-High and MYC-Low group, [Supplementary Table S3](#sup1){ref-type="supplementary-material"}), as revealed by OPLS-DA models (R2Y=0.957, Q2=0.549 for ESI+, R2Y=0.931, Q2=0.491 for ESI−, [Figure 1e](#fig1){ref-type="fig"}).

To elucidate the regulatory mechanism of MYC on lymphoma choline metabolism, cellular levels of choline, PC(16:0/22:6), LPC(16:0) and LPC(18:0) were assessed by UPLC-triple quadrupole mass spectrometry. Compared with untreated or negative control (CON siRNA-transfected) cells, 10058-F4-treated or *MYC* siRNA-transfected B-lymphoma cells displayed a significant decrease in cellular levels of choline and its phosphorylated derivatives ([Figure 1f](#fig1){ref-type="fig"} and [Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}).

Together, these data indicated that MYC overexpression is related to aberrant choline metabolism.

MYC dysregulated B-lymphoma choline metabolism by transcriptional activation of PCYT1A
--------------------------------------------------------------------------------------

As schematically summarized in [Figure 2a](#fig2){ref-type="fig"}, choline is catalyzed to phosphatidylcholine (PC), which is regulated by PCYT1A. Downstream metabolites of PC mainly include lysophoaphatidyl choline (LPC), which is regulated by phospholipase A2 (PLA2, encoded by *PLA2G4C*). When HEK-293T cells were transfected with pCMV6-*MYC* plasmid ([Figure 2b](#fig2){ref-type="fig"}, left panel), ectopic expression of MYC resulted in remarkably higher levels of *PCYT1A* and *PLA2G4C* (main regulatory enzymes) than those of vehicle-transfected cells (pCMV6-ct, [Figure 2b](#fig2){ref-type="fig"}, middle panel). To identify the key enzyme directly regulated by MYC, luciferase reporter assay was performed on HEK-293T cells and regions of promoter from human genomic DNA were cloned into a dual luciferase reporter vector GV238. The results showed that MYC enhances the gene and protein expression of PCYT1A ([Figure 2b](#fig2){ref-type="fig"}). Putative potential conserved MYC binding site within the regulatory region of *PCYT1A* promoter were predicted using JASPAR database (<http://jaspar.genereg.net/cgi-bin/jaspar_db.pl>). Chromatin immunoprecipitation assay was conducted in DB cells to verify the physiological interaction of MYC with promoter region of *PCYT1A*. MYC was able to bind with *PCYT1A* and the binding activity declined upon treatment with 10058-F4 or transfection with *MYC* siRNA ([Figure 2c](#fig2){ref-type="fig"}). Moreover, when luciferase reporter assay was performed on HEK-293T cells with MYC binding site mutation, the transcriptional activity of *PCYT1A* was no longer altered by MYC overexpression ([Figure 2d](#fig2){ref-type="fig"}).

To gain insight into the biological role of MYC-induced aberrant choline metabolism in B-cell lymphoma, DB and Ramos cells were either treated with MYC inhibitor 10058-F4 or transfected with *MYC* siRNA ([Figure 2e](#fig2){ref-type="fig"}, left panel). The results showed that both pharmaceutical and molecular inhibition of MYC induce B-lymphoma cell necroptosis, as revealed by co-immunoprecipitation with increased binding activity between RIP1, RIP3, and specific downstream mediator of necroptosis MLKL (RIP1/RIP3/MLKL complex, [Figure 2e](#fig2){ref-type="fig"}, right panel).^[@bib24]^ Meanwhile, lymphoma cell necroptosis (swelling mitochondria and intact nuclei membrane) was further confirmed by transmission electron microscopy ([Figure 2f](#fig2){ref-type="fig"}).

Therefore, through transcriptional activation of *PCYT1A,* MYC induced aberrant choline metabolism in B-lymphoma cells, resulting in an increased expression of PCYT1A, the major isoform of choline phosphatecytidylyl transferase required for phosphatidylcholine synthesis and an inhibition of B-lymphoma cell necroptosis.

*PCYT1A* modulated MYC-mediated B-lymphoma cell necroptosis in a mitophagy-dependent manner and was related to disease progression in DLBCL
-------------------------------------------------------------------------------------------------------------------------------------------

To determine the functional consequence of MYC-induced *PCYT1A* activation on DLBCL, B-lymphoma cells were transfected with siRNA targeting *PCYT1A* (*PCYT1A* siRNA). As confirmed by western blot, molecular silencing of *PCYT1A* resulted in decreased PCYT1A expression, whereas MYC remained constant ([Figure 3a](#fig3){ref-type="fig"}). Compared with negative control (CON siRNA), *PCYT1A* siRNA-transfected cells exhibited remarkable growth inhibition ([Figure 3b](#fig3){ref-type="fig"}) and necroptosis induction ([Figure 3c](#fig3){ref-type="fig"} and [Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}). Mitophagy is a selective form of macro-autophagy in which mitochondrial are selectively degraded in autophagy lysosomes and functions as a tumor suppressor.^[@bib25]^ Molecular silencing of *PCYT1A* increased mitophagy, as evaluated by co-immunofluorescence of LC3A/B with mitochondrial (MTC, [Figure 3d](#fig3){ref-type="fig"} and [Supplementary Figure S2B](#sup1){ref-type="supplementary-material"}). Meanwhile, B-lymphoma cell necroptosis was reversed by an addition of mitophagy inhibitor Mdivi-1 ([Figure 3c](#fig3){ref-type="fig"}, upper panel and [Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}), suggesting that *PCYT1A* induced necroptosis in a mitophagy-dependent manner.

Clinically, *PCYT1A* mRNA was significantly increased in tumor samples of 108 patients with DLBCL, as compared to reactive hyperplasia ([Figure 3e](#fig3){ref-type="fig"}). The patients with *PCYT1A* expression level over and equal to the median value 2.335 were regarded as *PCYT1A*-High group, whereas those below the median value were included in *PCYT1A*-Low group. Increased MYC positivity was more frequently observed in *PCYT1A*-High group than in *PCYT1A*-Low group ([Figure 3f](#fig3){ref-type="fig"}). Accordingly, representing as the main metabolite of choline metabolic pathway, serum PC(16:0/22:6) level was significantly lower in *PCYT1A*-High group than in *PCYT1A*-Low group ([Figure 3g](#fig3){ref-type="fig"}). *PCYT1A* overexpression was also associated with an International Prognostic Index, indicating intermediate-high and high-risk ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Therapeutic targeting of *PCYT1A* by BBR counteracted MYC-induced B-lymphoma cell growth via mitophagy-dependent necroptosis
----------------------------------------------------------------------------------------------------------------------------

At a clinically achievable concentration,^[@bib17]^ lipid-lowering alkaloid BBR inhibited B-lymphoma cell growth in a time- and dose-dependent manner ([Figure 4a](#fig4){ref-type="fig"}), consistent with the induction of necroptosis and the presence of mitophagy ([Figures 4b and c](#fig4){ref-type="fig"}). The gene and protein expression of PCYT1A were significantly downregulated by BBR, while MYC protein remained constant ([Figure 4d](#fig4){ref-type="fig"}). To clarify how BBR targeted PCYT1A, *PCYT1A* promoter activity was analyzed by transfecting DB cells with the *PCYT1A* promoter reporter plasmid. No significant difference in reporter activity was found between the untreated group and the BBR group ([Figure 4e](#fig4){ref-type="fig"}, left panel), prompting us to examine the possibility that BBR treatment may affect the stability of *PCYT1A* mRNA, resulting in lower expression levels of PCYT1A. The stability of *PCYT1A* mRNA was then estimated by measuring mRNA levels after treatment with Actinomycin D (5 μg/ml), a nucleic acid synthesis inhibitor, for the indicated times by quantitative real-time PCR. The results showed that BBR decreases the transcript stability and promotes the degradation of *PCYT1A* mRNA ([Figure 4e](#fig4){ref-type="fig"}, right panel). Although BBR could downregulate a series of kinases, including PI3K/AKT, MAPK, and CDKs,^[@bib26],\ [@bib27]^ these changes were not obvious in MYC-overexpressing DB cells ([Figure 4f](#fig4){ref-type="fig"}, left panel). Of note, resistance to BBR was observed in B-lymphoma cells transfected with pCMV6-*PCYT1A*, as compared to pCMV6-ct ([Figure 4f](#fig4){ref-type="fig"}, right panel), which confirmed that the downregulation of PCYT1A is a key event in BBR-induced cell growth inhibition. Moreover, compared to vehicle-transfected cells (pCMV6-ct), ectopic expression of MYC (pCMV6-*MYC*) induced significantly increased IC50 of DB cells towards chemotherapeutic agents like doxorubicin, cisplatin and gemcitabine (but not BBR). In these MYC-overexpressing cells, molecular silencing of *PCYT1A* sensitized cells to these chemotherapeutic agents ([Figure 4g](#fig4){ref-type="fig"} and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}).

BBR exhibited *in vivo* anti-lymphoma activity and induced *in situ* necroptosis.
---------------------------------------------------------------------------------

In the murine model established with subcutaneous injection of *PCYT1A* shRNA-transfected DB cells or negative control (CON shRNA), the size of xenograft tumors in the *PCYT1A* shRNA groups were significantly smaller than those of the CON shRNA group ([Figure 5a](#fig5){ref-type="fig"}, upper panel). Accordingly, in the murine model established with subcutaneous injection of DB cells, the size of xenograft tumors in the BBR group were significantly smaller than those of the untreated group after 6 days of treatment ([Figure 5a](#fig5){ref-type="fig"}, lower panel).^[@bib11]^ C-Choline micro-positron emission tomography/computed tomography was then carried out to visualize choline metabolism of tumors a week following the treatment. Compared with those in untreated mice, standardized uptake value intensity of tumors was significantly reduced in the BBR-treated mice ([Figure 5b](#fig5){ref-type="fig"}). As *in vitro* study, PCYT1A expression was decreased in the tumors of the BBR group, without any obvious change in the MYC protein ([Figure 5c](#fig5){ref-type="fig"}). To search for more evidence of *in situ* tumor cell necroptosis, ultrastructural study was performed on mice tumor. Typical cell necroptosis (swelling mitochondria and intact nuclei membrane) and mitophagy (increased mitochondrial density and accumulation of mitochondria within the double-membrane autophagy lysosomes)^[@bib14],\ [@bib25]^ were frequently observed in BBR-treated tumors ([Figure 5d](#fig5){ref-type="fig"}). Accordingly, serum levels of choline, as well as its phosphorylated derivatives PC(16:0/22:6), LPC(16:0) and LPC(18:0) were also restored by BBR treatment ([Figure 5e](#fig5){ref-type="fig"}).

These results provided *in vivo* evidence that progression of MYC-driven lymphoma can be tackled by altering downstream effector of choline metabolism with lipid-lowering agents.

Discussion
==========

Growing evidence suggest that the activation of oncogenes can reprogram tumor cell metabolism.^[@bib28]^ MYC is a key oncogene and critically involved in lipid synthesis, including those of cholesterol, fatty acid and glycerophospholipid.^[@bib12],\ [@bib29],\ [@bib30]^ Here we support a direct link between MYC overexpression and dysregulated choline metabolism (a major component of glycerophospholipids). These data in turn highlight the pivotal role of oncogenic MYC on lipid metabolism.

PCYT1A is the major isoform for the key enzyme CTP (choline phosphate cytidylyltransferase), essential for PC synthesis during lipid metabolism. In neuroblastoma, MYC modulates lipid synthesis by coordinating with MondoA.^[@bib29]^ As for lung cancer, MYC upregulates cytosolic phospholipase A2 and increases phosphatidylinositols and arachidonate-containing phospholipids, which are required for tumor cell survival and proliferation.^[@bib31]^ In the present study, *PCYT1A* was upregulated by MYC and contributed to dysregulated choline metabolic pathways, suggesting an alternative mechanism involved in MYC-mediated lymphoma cell metabolism and tumor progression. This is consistent with experimental findings in intestinal epithelial, which shows that PCYT1A determines malignant transformation of their normal counterparts.^[@bib32]^

Choline and its phosphorylated derivatives are implicated in the initiation and execution of necroptosis, an alternative caspase-independent cell death by modulating RIP1/RIP3 complex, also known as necrosome.^[@bib33]^ Alterations in lipid metabolism may damage cellular and subcellular membrane, cause imbalance between mitochondrial fusion and fission, initiate mitophagy and lead to necroptosis. Therefore, *PCYT1A* may not only act as a downstream effector of MYC on regulation of choline metabolism, but also a biomarker of MYC-mediated lymphoma cell necroptosis and lymphoma progression in DLBCL.

It is promising to treat oncogene-driven tumors through targeting downstream cell metabolism. For example, MYC-mediated glutamine metabolism could be modulated by glutaminase-specific inhibitor, which diminishes tumorigenesis and prolongs the survival of the mice with MYC-associated hepatocellular carcinoma.^[@bib34]^ Furthermore, inhibition of fatty acid oxidation has recently been proposed as a potential treatment for triple-negative breast cancer with MYC overexpression.^[@bib35]^ BBR is a quartenary ammonium salt belonging to the proto-berberine group of isoquinolone alkaloids and extracted from Chinese herbs known for its diverse pharmacological properties, notably the lipid-lowering effect.^[@bib16]^ The effect of BBR on mitochondrial fragmentation and depolarization has also been revealed^[@bib36]^ as contributing to necroptotic cell death in cancer cells.^[@bib37]^ We showed that BBR inhibits B-lymphoma cell growth by accelerating mRNA degradation of *PCYT1A* and inducing mitophagy-dependent necroptosis, suggesting an alternative therapeutic relevance of BBR on MYC-High lymphoma. In addition, necroptosis may arise from chemotherapy treatment, accounting for the cell death observed in apoptosis-defective tumor cells.^[@bib38]^ Induction of necroptosis to bypass apoptosis and to overcome chemoresistance has been achieved in hematological malignancies, such as acute myeloid leukemia and MLL-rearranged acute lymphoblastic leukemia.^[@bib39],\ [@bib40],\ [@bib41]^ Consistently, our data further opened up promising treatment avenues for BBR to reverse the chemoresistant effect of MYC by affecting MYC-downstream effectors.

In conclusion, MYC positively regulated *PCYT1A* expression and was responsible for the dysregulation of choline metabolism in DLBCL. These metabolic alterations could be reversed by lipid-lowering agent BBR, providing a clinical rationale of lipid-lowering strategy in treating MYC-high lymphoma.
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![MYC was overexpressed and related to aberrant choline metabolism in DLBCL. (**a**) MYC protein was High (⩾40%) in 47 of 108 (44%) patients with DLBCL. (**b**) The score plots of the principal component analysis (PCA) models (left panel) were set up using data from 15 MYC-High DLBCL cases (green plots), 15 MYC-Low DLBCL cases (blue plots) of the training set and 10 repeated quality controls (QCs, red plots). The score plots of the orthogonal partial least-squared discrimination analysis (OPLS-DA) models (middle panel) discriminated the MYC-High group (green plots) from the MYC-Low group (blue plots), which was confirmed by response permutation test (RPT, right panel). (**c**) Enrichment of KEGG pathways was performed on all the dysregulated metabolites using ConsensusPathDB. X-axis displayed *P*-values that were generated by --Log(P) function. The *P*\<0.05 and---Log(P)\>1.30 were considered significant. (**d**) Genesets of choline metabolism in cancer and glycerophospholipid metabolism pathway were analyzed by gene network and pathway analysis on microarray data of nine non-GCB DLBCL cases according to MYC expression (left panel). Significantly dysregulated genes involved in the metabolic pathways were shown in right panel. Shades of red and green represented high or low expression. (**e**) The OPLS-DA score plots confirmed a global metabolic difference between the MYC-High group (*N*=25, green plots) and the MYC-Low group (*N*=25, blue plots) in the validation set. (**f**) B-lymphoma cell line DB was either treated with 10058-F4 (40 μ[M]{.smallcaps}) for 48 h or transfected with *MYC* siRNA. Expression of Choline, PC(16:0/22:6), LPC(16:0) and LPC(18:0) were detected by UPLC-triple quadrupole mass spectrometry. Data in **f** were represented as mean±s.e.m. Assay in **f** was set up in triplicate.](bcj201761f1){#fig1}

![MYC acted on lymphoma choline metabolism by regulating *PCYT1A* expression. (**a**) Schematic description of choline metabolism. *PCYT1A*, phosphate cytidylyltransferase 1 choline-α *PLA2G4C*, phospholipase A; PC, phosphatidylcholine; LPC, lysophoaphatidylcholine. (**b**) HEK-293T cells were transfected with pCMV6-*MYC* plasmid or control plasmid (pCMV6-ct). The efficiency of transfection was confirmed by western blot (left panel). Expression of *PCYT1A* and *PLA2G4C* were assessed by quantitative real-time PCR (middle panel). HEK-293T cells were transfected with promoter-driven luciferase reporter of *PCYT1A* and *PLA2G4C*. Luciferase reporter activity was measured at 24 h after transfection (right panel). (**c**) Schematic diagram represented the regulatory region of *PCYT1A* promoter (upper panel). The activity of MYC binding to the *PCYT1A* promoter was measured by chromatin immunoprecipitation assay in DB cells either treated with 10058-F4 (40 μ[M]{.smallcaps}) for 48 h or transfected with *MYC* siRNA. DNA--protein complexes from DB cells were precipitated with anti-MYC antibody and amplified with primers amplifying MYC binding sites on *PCYT1A* promoter using PCR and quantitative real-time PCR (lower panel). Antibody against RNA Polymerase II was referred as positive control. Nonspecific IgG was referred as negative control. (**d**) Schematic diagram represented the *PCYT1A* promoter reporters with or without mutation of MYC binding site (left panel). HEK-293T cells were transfected with mutated promoter-driven luciferase reporter of *PCYT1A*. Luciferase reporter activity was measured at 24 h after transfection (right panel). (**e**) Co-immunoprecipitation showed increased formation of RIP1/RIP3/MLKL complex in DB and Ramos cells, either treated with 10058-F4 (DB, 40 μ[M]{.smallcaps}; Ramos, 30 μ[M]{.smallcaps}) for 48 h or transfected with *MYC* siRNA. (**f**) Transmission electron microscopy showed typical necroptotic cells after 10058-F4 treatment or *MYC* siRNA transfection. Data in **b**, **c** and **d** were represented as mean±s.e.m. Assays in **b**, **c** and **d** were set up in triplicate.](bcj201761f2){#fig2}

![*PCYT1A* was related to mitophagy-dependent necroptosis and disease progression in DLBCL. (**a**) Protein levels of PCYT1A and MYC in DB and Ramos cells transfected with *PCYT1A* siRNA or CON siRNA were assessed by western blottig. (**b**, **c**) Cell growth (**b**) and necroptosis (**c**) were detected in cells transfected with *PCYT1A* siRNA or treated with mitophagy inhibitor Mdivi-1 (50 μ[M]{.smallcaps}). (**d**) Representative immunofluorescence images of LC3A/B (red) and mitochondrial (MTC, green) in DB cells transfected with *PCYT1A* siRNA1 or CON siRNA. Cells were counterstained with 4\',6-diamidino-2-phenylindole (DAPI) (blue). (**e**) *PCYT1A* gene expression was assessed by quantitative real-time PCR in DLBCL (*n*=108) and reactive hyperplasia (*n*=20). (**f**, **g**) Tumor MYC expression (**f**) and serum PC(16:0/22:6) level (**g**) were calculated according to *PCYT1A* expression in DLBCL. Data in **b**, **e** and **g** were represented as mean±s.e.m. Assay in **b** was set up in triplicate.](bcj201761f3){#fig3}

![Therapeutic targeting of *PCYT1A* by berberine (BBR) in B-lymphoma cells. (**a**) Growth inhibition was measured in DB and Ramos cells treated with BBR. (**b**, **c**) Necroptosis (**b**) and mitophagy (**c**) were detected in BBR-treated cells (30 μ[M]{.smallcaps} and 20 μ[M]{.smallcaps}, respectively) for 48 h. (**d**) PCYT1A was assessed in DB cells by quantitative real-time PCR and western blotting. (**e**) *PCYT1A* promoter plasmid and pRL-TK were co-transfected into DB cells. BBR (30 μ[M]{.smallcaps}) was added to cells 12 h or 24 h before cell lysis. Cells were collected and firefly and *Renilla* luciferase activity were measured (left panel). Actinomycin D (5 μg/ml) was added to DB cells for different intervals, either alone or treated with BBR (30 μ[M]{.smallcaps}) for 24 h (right panel). (**f**) p-AKT, p-ERK and CDK6 were assessed in DB cells by western blot (left panel). Comparing with the pCMV6-ct-transfected cells, IC50 and IC20 of BBR were increased in DB cells transfected with pCMV6-*PCYT1A* (right panel). (**g**) Comparing with the pCMV6-ct-transfected cells, IC50 of doxorubicin, but not BBR, was increased in DB cells transfected with pCMV6-*MYC*. MYC-induced increase of IC50 was decreased by *PCYT1A* siRNA, as compared with negative control (CON siRNA). Data in **a**, **d**, **e**, **f** and **g** were represented as mean±s.e.m. Assays in **a**, **d**, **e**, **f** and **g** were set up in triplicate.](bcj201761f4){#fig4}

![*In vivo* activity of BBR on murine xenograft B-lymphoma model. (**a**) Tumor size of xenograft B-cell lymphoma with subcutaneous injection of DB cells transfected with *PCYT1A* shRNA or control shRNA (CON shRNA, upper panel, *N*=5 for each group). Tumor size was measured in BBR group and the untreated group in xenograft B-cell lymphoma with subcutaneous injection of DB cells (lower panel, *N*=10 for each group). \*\*\**P*\<0.001, \*\**P*\<0.01 and \**P*\<0.05 comparing with the untreated group. (**b**) ^11^C-Choline micro-positron emission tomography/computed tomography was performed one week after BBR treatment and standardized uptake value (SUV) intensity was observed. (**c**) PCYT1A and MYC expression were detected by immunohistochemistry. (**d**) Necroptosis and mitophagy were observed under transmission electron microscopy. (**e**) Serum levels of choline and its phosphorylated derivatives were measured by UPLC-triple quadrupole mass spectrometry. Data in **a** and **e** were represented as mean±s.e.m. Assay in **e** was set up in five mice.](bcj201761f5){#fig5}
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